Komal Jhaveri/X
May 8, 2025, 13:38
Komal Jhaveri: First Phase III Trial to Demonstrate Benefit of Enhertu in Early Breast Cancer
Komal Jhaveri, Patricia and James Cayne Chair for Junior Faculty, posted on LinkedIn:
“Hot off the press- The DESTINY-Breast11 Phase III trial demonstrated that trastuzumab deruxtecan followed by paclitaxel, trastuzumab, and pertuzumab (THP) improved pathologic complete response rates compared to the standard neoadjuvant regimen of dose-dense doxorubicin and cyclophosphamide followed by THP in patients with high-risk, locally advanced HER2-positive early-stage Breast Cancer.
Trastuzumab deruxtecan followed by THP had a favourable safety profile, avoiding some of the long-term cardiovascular risks. Although event-free survival data are still immature, early trends favoured the trastuzumab deruxtecan regimen.
Awaiting details of these data that will be presented at an upcoming conference.
This is right on the heels of DB-09 that reported statistically significant and clinically meaningful benefit with TDXD plus Pertuzumab compared to THP in first line metastatic setting. Data to be presented by Sara Tolaney at American Society of Clinical Oncology (ASCO) in a few weeks.”
More posts featuring Enhertu.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 8, 2025, 13:09
May 8, 2025, 12:36
May 8, 2025, 11:36